Trial Profile
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Pirtobrutinib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
- Acronyms BRUIN
- Sponsors Loxo Oncology
- 25 Mar 2024 Planned End Date changed from 1 Apr 2024 to 1 Jan 2028.
- 25 Mar 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Sep 2027.
- 12 Dec 2023 Results indirectly comparing ZUMA-2 and BRUIN trial evaluating unanchored MAIC to estimate the relative treatment effects of these therapies in the post-BTKi setting for R/R MCL, presented at the 65th American Society of Hematology Annual Meeting and Exposition